- |||||||||| Trial primary completion date: FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=50, Recruiting, Trial primary completion date: Jul 2015 --> Jul 2020 Trial primary completion date: May 2015 --> May 2016
- |||||||||| Enrollment closed, Trial primary completion date, Metastases: Molecularly Tailored Therapy for Pancreas Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=20, Active, not recruiting, Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2015
- |||||||||| onartuzumab (RG3638) / Roche
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Aug 12, 2015 P3, N=564, Active, not recruiting, Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2013 --> Sep 2014 N=800 --> 564 | Recruiting --> Active, not recruiting
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) (clinicaltrials.gov) - Aug 12, 2015 P=N/A, N=734, Active, not recruiting, N=800 --> 564 | Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=1000 --> 734 | Trial primary completion date: Jun 2016 --> Mar 2016
- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, HEOR, Combination therapy, Metastases: AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) - Aug 12, 2015 P3, N=183, Completed, Recruiting --> Active, not recruiting | N=1000 --> 734 | Trial primary completion date: Jun 2016 --> Mar 2016 Active, not recruiting --> Completed
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: Be TRI: A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC (clinicaltrials.gov) - Aug 5, 2015 P2, N=65, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> May 2017
- |||||||||| rosmantuzumab (OMP-131R10) / Mereo Biopharma
Enrollment open, Combination therapy, Metastases: A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 (clinicaltrials.gov) - Aug 2, 2015 P1, N=50, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> May 2017 Active, not recruiting --> Recruiting
|